GREY:IPHAF - Post Discussion
Post by
antoninus on Aug 04, 2010 2:48pm
lux senior management
Founder-chief operating officer
Mr. Atwell served as Director of Transplantation for Roche within the U.S., where he was responsible for the launch and growth of CellCept® into the leading immunosuppressive within the U.S. Market. This growth was based on the ability to build a sustainable franchise based on market leadership, a robust clinical program, and strong community based programs
Founder- chief medical officer
Prior to joining Enzon, Dr. Anglade served as Medical Director and Team Leader at Roche Laboratories, Inc. in the areas of virology and transplantation marketing. While at Roche, Dr. Anglade led a diverse team in the development and implementation of post-marketing studies with a budget exceeding $15 million for its transplantation (CellCept® and Zenapax®) and virology (Cytovene®) franchises
Be the first to comment on this post